Gelatinases as Markers of Chronic Alcohol Consumption:

A Pilot Study in Uruguay

  • Marta Marco Facultad de Medicina. Universidad de la República
  • Daniela Boragno
  • Paola Rodríguez Facultad de Medicina. Universidad de la República
  • Victoria Mestre Cordero
  • Natalia Pereira Facultad de Medicina. Universidad de la República
  • Patricia Berasain Facultad de Medicina. Universidad de la República
  • Florencia Cadenas
  • Cecilia Rodríguez Rodríguez Facultad de Medicina. Universidad de la República
  • Alejandra Moreira Facultad de Medicina. Universidad de la República
Keywords: Gelatinases

Abstract

Chronic alcohol consumption in Uruguay is a growing problem, however, determinations of consensual biomarker are not performed systematically neither potential markers are explored. To validate the hypothesis that matrix metalloproteinases with gelatinase activity are biomarkers of chronic alcohol consumption, blood samples of 100 alcoholics that began medical treatment at the Unidad de Trastornos
Relacionados con el Alcohol and 50 healthy non-alcoholic donors were evaluated. Alcoholic samples showed gelatinase activity that tripled that of controls and small but significant increases in levels of gamma-glutamyl transferase, aspartate-aminotransferase and mean cellular volume. Carbohydrate deficient transferrin values were lower in alcoholics than in controls. These results allow proposing gelatinases as the most sensitive indicators of sustained alcohol consumption in the population analyzed since hepatic enzymes and mean cellular volume showed a tendency consistent with the literature but did not reach values associated with the
pathology. Since carbohydrate-deficient transferrin is considered the most sensitive and specific indirect biomarker of chronic alcohol consumption, lower values in alcoholics related to controls suggest methodological problems that could be solved by applying other measurement techniques or the presence of yet unknown interferences. Finally, these findings justify an extension of this pilot work, as well as additional studies focused on the participation of matrix metalloproteinases with gelatinase activity in the cascades of damage associated with chronic alcohol consumption.

Downloads

Download data is not yet available.

Author Biography

Marta Marco, Facultad de Medicina. Universidad de la República

Laboratorio de Biología Tumoral, Departamento de Bioquímica Clínica, Facultad de Química, Universidad de la República, Uruguay.

References

1. Junta Nacional de Drogas. VI Encuesta Nacional en Hogares sobre Consumo de Drogas, 2016. Montevideo: JND, 2016.Disponibleen:https://www.gub.uy/junta-nacional-drogas/sites/junta-nacional-drogas/files/documentos/publicaciones/201609_VI_encuesta_hogares_OUD_ultima_rev.pdf
2. Pratt D, Kaplan M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000; 342 (17): 1266-1271.
3. Conigrave K, Davies P, Haber P, Whitfield JB. Traditional markers of excessive alcohol use. Addiction. 2003; 98(Suppl2):31-43.
4. Wu A, Chanarin I, Levi AJ. Macrocytosis of chronic alcoholism. Lancet. 1974; 1(7862):829-831.
5. Helander A, Eriksson CJ. Laboratory tests for acute alcohol consumption: results of the WHO/ISBRA study on state and trait markers of alcohol use and dependence. AlcoholismClinExp Res. 2002; 26(7):1070-1077.
6. Andresen-Streichert H, Müller A, Glahn A, Skopp G, Sterneck M. Alcohol Biomarkers in Clinical and Forensic contexts. DtschÄrztebl Intl. 2018; 115(18):309-315.
7. Salmela K, Laitinen K, Nystrom M, Salaspuro M. Carbohydrate-deficient transferrin during 3 weeks' heavy alcohol consumption. Alcohol Clin Exp Res. 1994; 18(2):228-230.
8. Helander A, Wielders J, Anton R, Arndt T, Bianchi V, Deenmamode J, Jeppsson J, Whitfield J, Weykamp C, Schellenberg F. Reprint of Standardisation and use of the alcohol biomarker carbohydrate deficient transferrin (CDT). ClinChimActa. 2017; 467:15-20.
9. Delanghe JR, Helander A, Wielders JP, Pekelharing JM, Roth HJ, Schellenberg F, Born C, Yagmur E, Gentzer W, Althaus H. Development and multicenter evaluation of the N latex CDT direct immunonephelometric assay for serum carbohydrate-deficient transferrin. ClinChem. 2007; 53(6):1115-1121.
10. Pérez Carreras M, Castellano G. Hígado y alcohol.En: Montoro MA, GarcíaPagán JC(Eds.). Gastroenterología y Hepatología. AEG: Madrid, 2012. Cap. 55. p. 799-814.
11. Flores-Bastías O, Karahanian E. Neuroinflammation produced by heavy alcohol intake is due to loops of interactions between Toll-like 4 and TNF receptors, peroxisome proliferator-activated receptors and the central melanocortin system: Anovel hypothesis and new therapeutic avenues. Neuropharmacology 2018; 128:401-407.
12. Galliera E, Tacchini L, CorsiRomanelli MM. Matrix metalloproteinases as biomarkers of disease: updates and new insights. ClinChem Lab Med. 2015; 53(3):349-355.
13. Mittal R, Patel AP, Debs LH, Nguyen D, Patel K, et al. Intricate Functions of Matrix Metalloproteinases in Physiological and Pathological Conditions. J Cell Physiol. 2016; 231(12):2599-2621.
14. Fingleton, B. Matrix metalloproteinases as regulators of inflammatory processes. BiochimBiophysActa. 2017; 1864(11PtA):2036-2042.
15. Saunders J, Aasland O, Babor T, De la Fuente J, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction.1993; 88(6):791-804.
16. Schumann G,Klauke R. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: preliminary upper reference limits obtained in hospitalized subjects. ClinChimActa 2003; 327(1-2):69-79.
17. Marco M, Baz A, Fernández C, González G, Hellman U, Salinas G, et al. A relevant enzyme in granulomatous reaction, active matrix metalloproteinase-9, found in bovine Echinococcusgranulosus hydatid cyst wall and fluid. Parasitol Res. 2006; 100(1):131-139.
18. Sillanaukee P, Kalela A, Seppa K, Hoyhtya M, Nikkari S. Matrix metalloproteinase-9 is elevated in serum of alcohol abusers. Eur J Clin Inv. 2002;32(4):225-229.
19. Hasselblatt M, Martin F, Maul O, Ehrenreich H, Kernbach-Wighton G. Persistent macrocytosis following abstinence from chronic alcohol use. JAMA. 2001;286(23): 2946.
20. Topic A, Djukic M. Diagnostic characteristics and application of alcohol biomarkers. ClinLab. 2013;59 (3-4):233-245.
21. Jastrzebska I, Zwolak A, Szczyrek M, Wawryniuk A, Skrzydlo-Radomanska B, Daniluk J. Biomarkers of alcohol misuse: recent advances and future prospects. PrzGastroenterol. 2016;11(2):78-89.
22. Niemelä O. Biomarker-Based Approaches for Assessing Alcohol Use Disorders. Int J Environ Res Public Health. 2016;13(2):166.
23. Stibler H, Borg S. The value of carbohydrate deficient transferrin as a marker of high alcohol consumption. En: Kuriyama K, Takaya A, Ishii H, ed. Biochemical and social aspects of alcohol and alcoholism. Amsterdam: ElsevierSciencePublishers B.V.; 1988. p. 503-506.
24. Torrente MP, Freeman WM, Vrana KE. Protein biomarkers of alcohol abuse. Expert Rev Proteomics. 2012;9(4):425-436.
25. De Feo TM, Fargion S, Duca L, Mattioli M, Cappellini MD, Sampietro M, Cesana BM, Fiorelli G. Carbohydrate-deficient Transferrin, a Sensitive Marker of Chronic Alcohol Abuse, Is Highly Influenced by Body Iron. Hepatology. 1999;29(3):658-663.
26. Bakhireva LN, Cano S, Rayburn WF, Savich RD, Leeman L, Anton RF, et al. Advanced gestational age increases serum carbohydrate-deficient transferrin levels in abstinent pregnant women. Alcohol Alcohol. 2012;47(6):683-687.
27. Chrostek L, Cylwik B, Gruszewska E, Panasiuk A, Szmitkowski M. N-latex CDT results in liver diseases. Alcohol Alcohol. 2012;47(4):428-432.
28. Whitfield JB, Dy V, Madden PAF, Heath AC, Martin NG, Montgomery GW. Measuring Carbohydrate-Deficient Transferrin by Direct Immunoassay: Factors Affecting Diagnostic Sensitivity for Excessive Alcohol Intake. Clin Chem. 2008;54(7):1158-1165.
29. Prystupa A, Boguszewska-Czubara A, Bojarska-Junak A, Torun-Jurkowska A, Rolinski J, Zaluska W. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann Agric Environ Med. 2015;22(2):325-328.
30. Madro A, Czechowska G, Slomka M, Celinski K, Szymonik-Lesiuk S, Kurzepa J. The Decrease of Serum MMP-2 Activity Corresponds to Alcoholic Cirrhosis Stage. Alcohol. 2012;46(2):155-157.
31. Kuyvenhoven J, van Hoek B, Blom E, van Duijn W, Hanemaaijer R, Verheijen JH, et al. Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. ThrombHaemost. 2003;89(4):718-725.
32. Chen J, Conigrave KM, Macaskill P, Whitfield JB, Irwig L. Combining carbohydrate-deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol & Alcoholism 2003;38(6):574-582.
33. Stefaniuk M, Beroun A, Lebitko T, Markina O, Leski S, Meyza K, et al. Matrix Metalloproteinase-9 and Synaptic Plasticity in the Central Amygdala in Control of Alcohol-Seeking Behavior. Biol Psychiatry. 2017;81(11):907-917.
Published
2020-05-10
How to Cite
Marco, M., Boragno, D., Rodríguez, P., Mestre Cordero, V., Pereira, N., Berasain, P., Cadenas, F., Rodríguez, C. R., & Moreira, A. (2020). Gelatinases as Markers of Chronic Alcohol Consumption:: A Pilot Study in Uruguay. Anales De La Facultad De Medicina, 7(1), e2020v7n1a3. https://doi.org/10.25184/anfamed2020v7n1a3